Accumulated Other Comprehensive Income (Loss), Net of Tax of Pharma-Bio Serv, Inc. from 31 Oct 2010 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
Pharma-Bio Serv, Inc. quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax in USD history and change rate from 31 Oct 2010 to 31 Oct 2025.
  • Pharma-Bio Serv, Inc. Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending 31 Oct 2025 was $278,045, a 6% increase year-over-year.
Source SEC data
View on sec.gov
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Change (%)

Pharma-Bio Serv, Inc. Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $278,045 +$15,665 +6% 31 Oct 2025 10-K 29 Jan 2026 2025 FY
Q2 2025 $285,577 +$32,299 +13% 31 Jul 2025 10-Q 15 Sep 2025 2025 Q3
Q1 2025 $282,946 +$59,404 +27% 30 Apr 2025 10-Q 16 Jun 2025 2025 Q2
Q4 2024 $243,883 +$18,677 +8.3% 31 Jan 2025 10-Q 17 Mar 2025 2025 Q1
Q3 2024 $262,380 +$52,114 +25% 31 Oct 2024 10-K 29 Jan 2026 2025 FY
Q2 2024 $253,278 +$31,572 +14% 31 Jul 2024 10-Q 16 Sep 2024 2024 Q3
Q1 2024 $223,542 -$22,773 -9.2% 30 Apr 2024 10-Q 14 Jun 2024 2024 Q2
Q4 2023 $225,206 -$4,481 -2% 31 Jan 2024 10-Q 18 Mar 2024 2024 Q1
Q3 2023 $210,266 -$27,886 -12% 31 Oct 2023 10-K 29 Jan 2025 2024 FY
Q2 2023 $221,706 +$193,087 +675% 31 Jul 2023 10-Q 14 Sep 2023 2023 Q3
Q1 2023 $246,315 +$178,492 +263% 30 Apr 2023 10-Q 14 Jun 2023 2023 Q2
Q4 2022 $229,687 +$110,725 +93% 31 Jan 2023 10-Q 17 Mar 2023 2023 Q1
Q3 2022 $238,152 +$93,697 +65% 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q2 2022 $28,619 -$165,758 -85% 31 Jul 2022 10-Q 14 Sep 2022 2022 Q3
Q1 2022 $67,823 -$121,322 -64% 30 Apr 2022 10-Q 14 Jun 2022 2022 Q2
Q4 2021 $118,962 -$65,444 -35% 31 Jan 2022 10-Q 17 Mar 2022 2022 Q1
Q3 2021 $144,455 -$16,199 -10% 31 Oct 2021 10-K 30 Jan 2023 2022 FY
Q2 2021 $194,377 +$13,514 +7.5% 31 Jul 2021 10-Q 14 Sep 2021 2021 Q3
Q1 2021 $189,145 +$87,012 +85% 30 Apr 2021 10-Q 14 Jun 2021 2021 Q2
Q4 2020 $184,406 +$52,540 +40% 31 Jan 2021 10-Q 17 Mar 2021 2021 Q1
Q3 2020 $160,654 +$17,054 +12% 31 Oct 2020 10-K 11 Feb 2022 2021 FY
Q2 2020 $180,863 +$94,658 +110% 31 Jul 2020 10-Q 14 Sep 2020 2020 Q3
Q1 2020 $102,133 +$9,611 +10% 30 Apr 2020 10-Q 15 Jun 2020 2020 Q2
Q4 2019 $131,866 +$16,077 +14% 31 Jan 2020 10-Q 16 Mar 2020 2020 Q1
Q3 2019 $143,600 +$35,653 +33% 31 Oct 2019 10-K 01 Feb 2021 2020 FY
Q2 2019 $86,205 -$44,844 -34% 31 Jul 2019 10-Q 16 Sep 2019 2019 Q3
Q1 2019 $92,522 -$90,325 -49% 30 Apr 2019 10-Q 14 Jun 2019 2019 Q2
Q4 2018 $115,789 -$103,157 -47% 31 Jan 2019 10-Q 18 Mar 2019 2019 Q1
Q3 2018 $107,947 -$29,724 -22% 31 Oct 2018 10-K 29 Jan 2020 2019 FY
Q2 2018 $131,049 +$252,718 31 Jul 2018 10-Q 14 Sep 2018 2018 Q3
Q1 2018 $182,847 +$344,382 30 Apr 2018 10-Q 14 Jun 2018 2018 Q2
Q4 2017 $218,946 +$379,474 31 Jan 2018 10-Q 19 Mar 2018 2018 Q1
Q3 2017 $137,671 +$303,586 31 Oct 2017 10-K 29 Jan 2019 2018 FY
Q2 2017 $121,669 +$34,510 +22% 31 Jul 2017 10-Q 14 Sep 2017 2017 Q3
Q1 2017 $161,535 +$1,654 +1% 30 Apr 2017 10-Q 14 Jun 2017 2017 Q2
Q4 2016 $160,528 +$77,004 +32% 31 Jan 2017 10-Q 17 Mar 2017 2017 Q1
Q3 2016 $165,915 +$60,665 +27% 31 Oct 2016 10-K 29 Jan 2018 2017 FY
Q2 2016 $156,179 +$70,413 +31% 31 Jul 2016 10-Q 14 Sep 2016 2016 Q3
Q1 2016 $163,189 +$43,685 +21% 30 Apr 2016 10-Q 14 Jun 2016 2016 Q2
Q4 2015 $237,532 -$53,809 -29% 31 Jan 2016 10-Q 16 Mar 2016 2016 Q1
Q3 2015 $226,580 -$90,872 -67% 31 Oct 2015 10-K 31 Jan 2017 2016 FY
Q2 2015 $226,592 -$126,747 -127% 31 Jul 2015 10-Q 14 Sep 2015 2015 Q3
Q1 2015 $206,874 -$132,310 -177% 30 Apr 2015 10-Q 15 Jun 2015 2015 Q2
Q4 2014 $183,723 -$89,340 -95% 31 Jan 2015 10-Q 17 Mar 2015 2015 Q1
Q3 2014 $135,708 -$58,956 -77% 31 Oct 2014 10-K 29 Jan 2016 2015 FY
Q2 2014 $99,845 -$15,294 -18% 31 Jul 2014 10-Q 15 Sep 2014 2014 Q3
Q1 2014 $74,564 +$19,946 +21% 30 Apr 2014 10-Q 16 Jun 2014 2014 Q2
Q4 2013 $94,383 -$31,325 -50% 31 Jan 2014 10-Q 17 Mar 2014 2014 Q1
Q3 2013 $76,752 +$14,666 +16% 31 Oct 2013 10-K 29 Jan 2015 2014 FY
Q2 2013 $84,551 +$48,620 +37% 31 Jul 2013 10-Q 16 Sep 2013 2013 Q3
Q1 2013 $94,510 -$17,827 -23% 30 Apr 2013 10-Q 14 Jun 2013 2013 Q2
Q4 2012 $63,058 +$19,231 +23% 31 Jan 2013 10-Q 18 Mar 2013 2013 Q1
Q3 2012 $91,418 -$71,409 -357% 31 Oct 2012 10-K 29 Jan 2014 2013 FY
Q2 2012 $133,171 -$124,732 -1478% 31 Jul 2012 10-Q 14 Sep 2012 2012 Q3
Q1 2012 $76,683 30 Apr 2012 10-Q 14 Jun 2012 2012 Q2
Q4 2011 $82,289 31 Jan 2012 10-Q 16 Mar 2012 2012 Q1
Q3 2011 $20,009 -$791 -4.1% 31 Oct 2011 10-K 29 Jan 2013 2012 FY
Q2 2011 $8,439 31 Jul 2011 10-Q 14 Sep 2011 2011 Q3
Q3 2010 $19,218 31 Oct 2010 10-K/A 31 Jan 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.